

# Waverley Pharma Announces Changes to Board of Directors

WINNIPEG, MB, Nov. 22, 2023 /CNW/ - Waverley Pharma Inc. ("**Waverley Pharma**" or the "**Company**") (TSXV: WAVE), a Canadian pharmaceutical company, is pleased to announce that effective today, Larry Thiessen has been appointed to the Company's Board of Directors. Mr. Thiessen replaces Hellen Siwanowicz, who has resigned from her board position.

Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experience having previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25 years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba. He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation. Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University in Edmonton, Alberta.

Commenting on the changes, Dr. Albert Friesen, Chair of the Company's Board of Directors stated, "We would like to welcome Larry to the Board of Directors and are grateful for his ongoing commitment to Waverley Pharma. In addition, on behalf of management and directors of the Company, I would like to thank Hellen for her contributions over the years and wish her all the best in the future.

## About Waverley Pharma

Waverley Pharma is a pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the EU, United Kingdom and North American markets. The Company has developed two generic oncology products in the United States and Europe, namely pemetrexed and bortezomib. For more information on Waverley Pharma please visit [www.waverleypharma.com](http://www.waverleypharma.com).

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**

**Forward Looking Information:** *Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's potential product revenues, stage of development, additional capital requirements, risks associated with obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but*

*not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities.*

SOURCE Waverley Pharma Inc.

View original content: <http://www.newswire.ca/en/releases/archive/November2023/22/c4630.html>

%SEDAR: 00042362E

**For further information:** Haaris Uddin, Chief Financial Officer by phone: 204-478-5609 or by E-mail: [huddin@waverleypharma.com](mailto:huddin@waverleypharma.com), or visit [www.waverleypharma.com](http://www.waverleypharma.com)

CO: Waverley Pharma Inc.

CNW 17:00e 22-NOV-23